Online citations, reference lists, and bibliographies.
← Back to Search

Guidelines Of The European Respiratory Society And The European Society Of Thoracic Surgeons For The Management Of Malignant Pleural Mesothelioma

A. Scherpereel, P. Astoul, P. Baas, T. Berghmans, H. Clayson, P. de Vuyst, H. Dienemann, F. Galateau-Sallé, C. Hennequin, G. Hillerdal, C. le Péchoux, L. Mutti, J. Pairon, R. Stahel, P. van Houtte, J. V. van Meerbeeck, D. Waller, W. Weder
Published 2009 · Medicine

Cite This
Download PDF
Analyze on Scholarcy
Share
Malignant pleural mesothelioma (MPM) is a rare tumour but with increasing incidence and a poor prognosis. In 2008, the European Respiratory Society/European Society of Thoracic Surgeons Task Force brought together experts to propose practical and up-to-dated guidelines on the management of MPM. To obtain an earlier and reliable diagnosis of MPM, the experts recommend performing thoracoscopy, except in cases of pre-operative contraindication or pleural symphysis. The standard staining procedures are insufficient in ∼10% of cases. Therefore, we propose using specific immunohistochemistry markers on pleural biopsies. In the absence of a uniform, robust and validated staging system, we advice use of the most recent TNM based classification, and propose a three step pre-treatment assessment. Patient's performance status and histological subtype are currently the only prognostic factors of clinical importance in the management of MPM. Other potential parameters should be recorded at baseline and reported in clinical trials. MPM exhibits a high resistance to chemotherapy and only a few patients are candidates for radical surgery. New therapies and strategies have been reviewed. Because of limited data on the best combination treatment, we emphasise that patients who are considered candidates for a multimodal approach should be included in a prospective trial at a specialised centre.
This paper references
10.1158/0008-5472.CAN-05-4642
Genetic predisposition to fiber carcinogenesis causes a mesothelioma epidemic in Turkey.
A. Dogan (2006)
Palliative Care for Mesothelioma
Ahmedzai SaC (2006)
Illustrated Guide to the TMN Classification of Malignant Tumours. 5th Edn
Wittekind Ch (2004)
10.1023/A:1007691003600
Environmental exposure to asbestos and risk of pleural mesothelioma: review and meta-analysis
V. Bourdès (2004)
10.1016/J.IJROBP.2006.03.012
Fatal pneumonitis associated with intensity-modulated radiation therapy for mesothelioma.
A. Allen (2006)
10.1200/JCO.2007.12.5294
Symptoms and patient-reported well-being: do they predict survival in malignant pleural mesothelioma? A prognostic factor analysis of EORTC-NCIC 08983: randomized phase III study of cisplatin with or without raltitrexed in patients with malignant pleural mesothelioma.
A. Bottomley (2007)
UICC, International Union Against Cancer. TNM Atlas. Illustrated Guide to the TMN Classification of Malignant Tumours
Wittekind Ch (2004)
10.1016/J.JTCVS.2004.02.021
Prevention, early detection, and management of complications after 328 consecutive extrapleural pneumonectomies.
D. Sugarbaker (2004)
10.1097/00001622-200303000-00003
The role of new imaging techniques in diagnosis and staging of malignant pleural mesothelioma
R. Eibel (2003)
10.1002/14651858.CD003880.PUB4
Radiotherapy for malignant pleural mesothelioma.
E. Chapman (2006)
10.1016/J.RMED.2006.10.018
Guidelines of the French Speaking Society for Chest Medicine for management of malignant pleural mesothelioma.
A. Scherpereel (2007)
10.1016/j.lungcan.2008.04.001
The efficacy and safety of weekly vinorelbine in relapsed malignant pleural mesothelioma.
J. Stebbing (2009)
10.1097/JTO.0B013E31802F3813
Pemetrexed as Second-Line Treatment in Malignant Pleural Mesothelioma after Platinum-Based First-Line Treatment
J. Sørensen (2007)
10.1080/02656730601012508
Hyperthermia combined with intra-thoracic chemotherapy and radiotherapy for malignant pleural mesothelioma
Hongqiang Xia (2006)
10.1002/IJC.2910410409
Survival patterns for malignant mesothelioma: The seer experience
R. Spirtas (1988)
Experimental evaluation of potential anticancer agents VIII. Effects of certain nitrosoureas on intracerebral L1210 leukemia.
F. Schabel (1963)
10.1164/rccm.200802-258OC
Soluble mesothelin-related protein in an asbestos-exposed population: the dust diseases board cohort study.
E. Park (2008)
10.1016/J.LUNGCAN.2005.03.030
CT, RECIST, and malignant pleural mesothelioma.
A. Nowak (2005)
10.1093/ANNONC/MDH059
Modified RECIST criteria for assessment of response in malignant pleural mesothelioma.
M. Byrne (2004)
Radiotherapy for malignant pleural mesothelioma. Cochrane Database of Systematic Reviews 2006(3)
E BEChapman (2006)
10.1016/S1547-4127(04)00108-2
External beam radiation therapy for the treatment of pleural mesothelioma.
E. Baldini (2004)
Chemotherapy of malignant pleural
T Berghmans (2006)
10.1183/09031936.98.11061416
Guidelines for mineral fibre analyses in biological samples: report of the ERS Working Group. European Respiratory Society.
P. de Vuyst (1998)
10.1016/J.HOC.2005.09.009
Prognostic factors for mesothelioma.
J. Steele (2005)
A phase II trial of imatinib mesylate in patients with malignant mesothelioma
JL HAVillano (2004)
10.2967/jnumed.107.042333
Early Prediction of Response to Chemotherapy and Survival in Malignant Pleural Mesothelioma Using a Novel Semiautomated 3-Dimensional Volume-Based Analysis of Serial 18F-FDG PET Scans
R. Francis (2007)
10.1056/NEJMRA050152
Advances in malignant mesothelioma.
B. Robinson (2005)
10.1016/J.LUNGCAN.2004.10.005
Thalidomide in patients with malignant pleural mesothelioma.
P. Baas (2005)
10.1016/S1010-7940(01)00995-2
Palliative surgical debulking in malignant mesothelioma. Predictors of survival and symptom control.
A. Martin-Ucar (2001)
10.1136/thorax.57.2.187-a
Statement on malignant mesothelioma in the UK
M. Robinson (2002)
10.1200/JCO.20005.14.589
Randomized phase III study of cisplatin with or without raltitrexed in patients with malignant pleural mesothelioma: an intergroup study of the European Organisation for Research and Treatment of Cancer Lung Cancer Group and the National Cancer Institute of Canada.
J. Van Meerbeeck (2005)
Latent period for malignant mesothelioma of occupational origin.
B. Lanphear (1992)
World Health Organization Classification of Tumours. Pathology and Genetics. Tumours of the Lung, Pleura
W D Travis (2004)
10.1245/ASO.2003.03.022
Cytoreductive Surgery Combined With Intraoperative Hyperthermic Intrathoracic Chemotherapy for Stage I Malignant Pleural Mesothelioma
S. van Ruth (2003)
10.1136/oem.60.1.50
Update of predictions of mortality from pleural mesothelioma in the Netherlands
O. Segura (2003)
10.1067/MTC.2001.116560
A phase II trial of surgical resection and adjuvant high-dose hemithoracic radiation for malignant pleural mesothelioma.
V. Rusch (2001)
10.1200/JCO.2006.09.7634
Phase II study of erlotinib in patients with malignant pleural mesothelioma: a Southwest Oncology Group Study.
L. Garland (2007)
10.1200/JCO.1998.16.1.145
Prognostic factors in patients with pleural mesothelioma: the European Organization for Research and Treatment of Cancer experience.
D. Curran (1998)
10.1002/1097-0142(19830401)51:7<1209::AID-CNCR2820510707>3.0.CO;2-J
The james ewing lecture. The relationship between tumor mass and resistance to chemotherapy. Implications for surgical adjuvant treatment of cancer
V. DeVita (1983)
10.1136/oem.2005.023200
The French National Mesothelioma Surveillance Program
M. Goldberg (2006)
10.1007/978-3-642-82982-6
TNM Classification of Malignant Tumours
L. Sobin (1987)
UICC. TNM Atlas
C GFWittekind (2004)
10.1016/S0140-6736(07)60412-7
Ecological association between asbestos-related diseases and historical asbestos consumption: an international analysis
Ro-Ting Lin (2007)
10.6004/JNCCN.2012.0006
[Malignant pleural mesothelioma].
Q. Kong (1983)
10.1016/J.LUNGCAN.2005.03.032
Consensus report: pretreatment minimal staging and treatment of potentially resectable malignant pleural mesothelioma.
J. Van Meerbeeck (2005)
10.1378/CHEST.113.3.723
Factors predictive of survival among 337 patients with mesothelioma treated between 1984 and 1994 by the Cancer and Leukemia Group B.
J. Herndon (1998)
10.1200/JCO.2004.22.14_SUPPL.7200
A Phase II trial of imatinib mesylate in patients (pts) with malignant mesothelioma (MM).
J. Villano (2004)
10.1136/oem.17.4.260
Diffuse Pleural Mesothelioma and Asbestos Exposure in the North Western Cape Province
J. Wagner (1960)
The Use of Chemotherapy in Patients with Advanced Malignant Pleural Mesothelioma. A Quality Initiative of the Program in Evidence-based Care (PEBC), Cancer Care Ontario (CCO)
P Ellis (2005)
10.1093/ANNONC/MDI187
Second-line (post-study) chemotherapy received by patients treated in the phase III trial of pemetrexed plus cisplatin versus cisplatin alone in malignant pleural mesothelioma.
C. Manegold (2005)
EXPERIMENTAL EVALUATION OF POTENTIAL ANTICANCER AGENTS. XIII. ON THE CRITERIA AND KINETICS ASSOCIATED WITH "CURABILITY" OF EXPERIMENTAL LEUKEMIA.
H. Skipper (1964)
10.1200/JCO.2004.09.147
Assessing quality of life during chemotherapy for pleural mesothelioma: feasibility, validity, and results of using the European Organization for Research and Treatment of Cancer Core Quality of Life Questionnaire and Lung Cancer Module.
A. Nowak (2004)
10.1177/026921639601000405
Non-pharmacological intervention for breathlessness in lung cancer
J. Corner (1996)
10.1002/14651858.CD006165.pub3
Interventions for latent autoimmune diabetes (LADA) in adults.
S. Brophy (2011)
10.1093/OXFORDJOURNALS.AJE.A009616
Pleural mesothelioma: dose-response relation at low levels of asbestos exposure in a French population-based case-control study.
Y. Iwatsubo (1998)
10.1038/sj.bjc.6601000
Long-term results of intrathoracic chemohyperthermia (ITCH) for the treatment of pleural malignancies
O. Monneuse (2003)
10.1016/S0140-6736(08)60727-8
Active symptom control with or without chemotherapy in the treatment of patients with malignant pleural mesothelioma (MS01): a multicentre randomised trial
M. Muers (2008)
10.1016/S1010-7940(96)01008-1
Pleurectomy/decortication for palliation in malignant pleural mesothelioma: results of surgery.
O. Soysal (1997)
Multicenter trial of neoadjuvant chemotherapy followed by extrapleural pneumonectomy in malignant pleural mesothelioma
W Weder (2007)
World Health Organization Classification of Tumours. Pathology and Genetics. Tumours of the Lung, Pleura, Thymus and Heart
WD Travis (2004)
10.1289/ehp.9900
Modeling Mesothelioma Risk Associated with Environmental Asbestos Exposure
M. Maule (2007)
10.1016/S0959-8049(99)00229-4
Measurement of clinical and subclinical tumour response using [18F]-fluorodeoxyglucose and positron emission tomography: review and 1999 EORTC recommendations. European Organization for Research and Treatment of Cancer (EORTC) PET Study Group.
H. Young (1999)
10.1016/J.LUNGCAN.2005.03.007
The role of PET in the surgical management of malignant pleural mesothelioma.
R. Flores (2005)
10.1378/CHEST.108.3.754
Prevention of malignant seeding after invasive diagnostic procedures in patients with pleural mesothelioma. A randomized trial of local radiotherapy.
C. Boutin (1995)
10.1158/1078-0432.CCR-06-2144
Utility of Osteopontin and Serum Mesothelin in Malignant Pleural Mesothelioma Diagnosis and Prognosis Assessment
B. Grigoriu (2007)
10.1200/JCO.2007.25.18_SUPPL.7561
A multicenter U.S. trial of neoadjuvant pemetrexed plus cisplatin (PC) followed by extrapleural pneumonectomy (EPP) and hemithoracic radiation (RT) for stage I-III malignant pleural mesothelioma (MPM)
L. Krug (2007)
10.1002/1097-0142(19840915)54:6<961::AID-CNCR2820540602>3.0.CO;2-B
Chemotherapy of diffuse malignant mesothelioma. Phase II trials of single‐agent 5‐fluorouracil and adriamycin
V. Harvey (1984)
10.1634/THEONCOLOGIST.12-10-1215
Low-dose computed tomography screening for lung cancer and pleural mesothelioma in an asbestos-exposed population: baseline results of a prospective, nonrandomized feasibility trial--an Alpe-adria Thoracic Oncology Multidisciplinary Group Study (ATOM 002).
G. Fasola (2007)
10.1016/S0140-6736(00)04013-7
Genetic-susceptibility factor and malignant mesothelioma in the Cappadocian region of Turkey
Iman Roushdy-Hammady (2001)
Laboratory models: some historical perspective.
S. He (1986)
Phase II trial of imatinib mesylate in patients with advanced pleural mesothelioma
M PFMillward (2003)
10.1016/S0959-8049(02)80018-1
Phase II trial of ZD0473 as second-line therapy in mesothelioma.
G. Giaccone (2002)
10.1200/JCO.2006.09.9887
Phase III trial of pemetrexed plus best supportive care compared with best supportive care in previously treated patients with advanced malignant pleural mesothelioma.
J. Jassem (2008)
10.1016/0360-3016(91)90054-8
Deterioration in lung function following hemithorax irradiation for pleural mesothelioma.
P. Maasilta (1991)
10.1016/J.RADONC.2007.05.022
A randomised controlled trial of intervention site radiotherapy in malignant pleural mesothelioma.
N. O’Rourke (2007)
10.1001/ARCHSURG.1992.01420110032008
The James Ewing Lecture.
M. Brennan (1992)
EORTC 08031. The 9th international conference of the International Mesothelioma Interest Group
P Van Schil (2008)
10.1148/RG.241035058
Malignant pleural mesothelioma: evaluation with CT, MR imaging, and PET.
Z. Wang (2004)
10.1158/1078-0432.CCR-04-1940
Gefitinib in Patients with Malignant Mesothelioma: A Phase II Study by the Cancer and Leukemia Group B
R. Govindan (2005)
10.1007/s00520-005-0837-0
Measuring quality of life in patients with pleural mesothelioma using a modified version of the Lung Cancer Symptom Scale (LCSS): psychometric properties of the LCSS-Meso
P. Hollen (2005)
10.1136/thx.2007.087619
BTS statement on malignant mesothelioma in the UK, 2007
(2007)
10.1016/S0140-6736(03)14794-0
Mesothelin-family proteins and diagnosis of mesothelioma
B. Robinson (2003)
10.1002/cncr.22366
Efficacy and safety of first‐ or second‐line irinotecan, cisplatin, and mitomycin in mesothelioma
D. Fennell (2007)
EORTC 08031
P Van Schil (2008)
10.1097/JTO.0b013e318191520c
Phase II Study of Belinostat (PXD101), a Histone Deacetylase Inhibitor, for Second Line Therapy of Advanced Malignant Pleural Mesothelioma
S. Ramalingam (2009)
10.1038/sj.bjc.6601638
The Mesothelioma epidemic in Western Europe: an update
C. Pelucchi (2004)
10.1016/J.LUNGCAN.2005.04.010
Limited efficacy of imatinib mesylate in malignant mesothelioma: a phase II trial.
A. Mathy (2005)
10.1164/rccm.200806-955ED
Screening for mesothelioma: more harm than good?
J. Van Meerbeeck (2008)
10.1016/S0169-5002(03)00292-7
Inadequacy of the RECIST criteria for response evaluation in patients with malignant pleural mesothelioma.
R. V. van Klaveren (2004)
10.1056/nejmoa051185
Asbestos exposure, pleural mesothelioma, and serum osteopontin levels.
H. Pass (2005)
10.1093/ANNONC/MDM027
Malignant pleural mesothelioma: ESMO clinical recommendations for diagnosis, treatment and follow-up.
C. Manegold (2007)
Palliative care for mesothelioma
S Ahmedzai (2006)
A phase II trial of imatinib mesylate in patients with malignant mesothelioma
JL Villano (2004)
10.1016/J.LUNGCAN.2004.11.015
Raltitrexed-Oxaliplatin combination chemotherapy is inactive as second-line treatment for malignant pleural mesothelioma patients.
C. Porta (2005)
10.1136/oem.2004.018531
The additional risk of malignant mesothelioma in former workers and residents of Wittenoom with benign pleural disease or asbestosis
A. Reid (2005)
10.1378/CHEST.107.5.1454
Video-assisted thoracoscopic pleurectomy in the management of malignant pleural effusion.
D. Waller (1995)
10.1378/chest.129.1_suppl.174S
Habit cough, tic cough, and psychogenic cough in adult and pediatric populations: ACCP evidence-based clinical practice guidelines.
R. Irwin (2006)
EORTC 08031. the 9th international conference of the International Mesothelioma Interest Group 2008, Amsterdam, The Netherlands: p174 (abstract N°140)
P VanSchil (2008)
Phase II trial of imatinib mesylate in patients with advanced pleural mesothelioma
MPF Millward (2003)
[The experts' conference of the Société de Pneumologie de Langue Française (SPLF) on malignant pleural mesothelioma (MPM): useful and necessary recommendations].
A. Scherpereel (2006)
10.1183/09031936.00079407
Drain site radiotherapy in malignant pleural mesothelioma: a wasted resource
R. Muirhead (2007)
10.1016/S0169-5002(02)00180-0
Activity of chemotherapy and immunotherapy on malignant mesothelioma: a systematic review of the literature with meta-analysis.
T. Berghmans (2002)
10.1093/ANNONC/MDJ073
A randomised trial in malignant mesothelioma (M) of early (E) versus delayed (D) chemotherapy in symptomatically stable patients: the MED trial.
M. O'Brien (2006)
10.1200/JCO.2007.25.18_SUPPL.7526
Final analysis of a multi-center, double-blind, placebo-controlled, randomized phase II trial of gemcitabine/cisplatin (GC) plus bevacizumab (B) or placebo (P) in patients (pts) with malignant mesothelioma (MM)
T. Karrison (2007)
10.1097/00001622-200303000-00005
Indications and limitations of radiotherapy in malignant pleural mesothelioma
S. Senan (2003)
10.1093/ANNONC/MDM093
Multicenter trial of neo-adjuvant chemotherapy followed by extrapleural pneumonectomy in malignant pleural mesothelioma.
W. Weder (2007)
10.1007/978-3-642-10862-4
[Malignant mesothelioma].
J. Espinosa Arranz (1994)
10.1200/JCO.2003.11.136
Phase III study of pemetrexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma.
N. Vogelzang (2003)
10.1016/J.EJSO.2004.08.014
Improved survival with VATS pleurectomy-decortication in advanced malignant mesothelioma.
J. Halstead (2005)
10.1038/sj.bjc.6602307
The expected burden of mesothelioma mortality in Great Britain from 2002 to 2050
J. Hodgson (2005)
Laboratory models: some historical perspective.
H. Skipper (1986)
10.1002/1097-0142(20000615)88:12<2887::AID-CNCR32>3.0.CO;2-F
World Health Organization classification of tumors
P. Kleihues (2000)
World Health Organization Classification of tumors. Tumors of the lung, pleura, thymus and heart
WD BETravis (2004)
10.1016/J.EJCTS.2007.09.039
The role of video assisted thoracoscopic pleurectomy/decortication in the therapeutic management of malignant pleural mesothelioma.
A. Nakas (2008)
Chemotherapy for malignant pleural mesothelioma.
P. Janne (2003)
Physicians task force
JC Wagner (2006)
10.1378/CHEST.129.1.174
Grading strength of recommendations and quality of evidence in clinical guidelines: report from an american college of chest physicians task force.
G. Guyatt (2006)
10.1023/A:1026300619747
Pleural mesothelioma incidence in Europe: evidence of some deceleration in the increasing trends
F. Montanaro (2004)
Randomized trial of doxorubicin versus cyclophosphamide in diffuse malignant pleural mesothelioma.
P. Sørensen (1985)



This paper is referenced by
10.1016/J.MEDCLI.2014.08.005
Contribución del análisis del líquido pleural al diagnóstico de los derrames pleurales
L. Ferreiro (2015)
10.1159/000486578
Management and Survival of Pleural Mesothelioma: A Record Linkage Study
G. Carioli (2018)
10.3978/j.issn.2225-319X.2012.11.13
Extrapleural pneumonectomy and extended pleurectomy/decortication for malignant pleural mesothelioma: the Memorial Sloan-Kettering Cancer Center approach.
V. Rusch (2012)
Chirurgische Aspekte des malignen Pleuramesothelioms
Aus Sicht der Pathologie (2013)
10.1007/s10269-014-2395-x
Le mésothéliome pleural malin
J. Margery (2014)
10.1016/J.ARBRES.2014.06.005
Diagnóstico y tratamiento del mesotelioma pleural maligno
Francisco Rodríguez Panadero (2015)
10.1016/j.jtcvs.2019.08.027
Survival results in biphasic malignant pleural mesothelioma patients: A multicentric analysis.
Filippo Lococo (2019)
10.3389/978-2-88963-706-5
C1q: A Molecular Bridge to Innate and Adaptive Immunity
Uday Kishore (2020)
10.1007/978-3-319-52619-5_36-1
Radiation Therapy in Mesothelioma
Jonas Willmann (2019)
10.1016/S1877-1203(16)30135-5
Traitement du mésothéliome pleural malin en 2016
Arnaud Scherpereel (2016)
10.1016/J.MEDIPA.2014.11.001
Mesotelioma pleural maligno
Eva María García Atienza (2017)
10.13075/ijomeh.1896.00637
Validity of mesothelin in occupational medicine practice.
Petra Smolková (2016)
10.1371/journal.pone.0106742
Ratio of Intratumoral Macrophage Phenotypes Is a Prognostic Factor in Epithelioid Malignant Pleural Mesothelioma
R. Cornelissen (2014)
10.3390/ijms20174182
Building a Bridge between Chemotherapy and Immunotherapy in Malignant Pleural Mesothelioma: Investigating the Effect of Chemotherapy on Immune Checkpoint Expression
Elly Marcq (2019)
10.3390/medicina55080419
Mesothelioma Mortality Rates in Greece for the Period 2005–2015 Is Increased Compared to Previous Decades
Evdoxia Gogou (2019)
10.1016/j.lungcan.2011.08.009
An electronic nose distinguishes exhaled breath of patients with Malignant Pleural Mesothelioma from controls.
S. Dragonieri (2012)
10.1016/J.RMR.2016.10.005
Irradiation prophylactique des orifices de drainage dans le mésothéliome pleural : un essai de phase 3, « SMART » mais pas trop…
S. Brosseau (2016)
10.1265/JJH.66.558
[Current status and future direction of Japan's clinical trial for malignant pleural mesothelioma].
S. Hasegawa (2011)
10.1016/J.RMR.2012.02.012
Les différentes pathologies pleuropulmonaires liées à l’amiante : définitions, épidémiologie et évolution
J. Ameille (2012)
10.1164/rccm.201203-0465PP
Malignant pleural effusion: tumor-host interactions unleashed.
G. Stathopoulos (2012)
10.1007/s10405-014-0777-9
Management von Pleuraerkrankungen
W. Frank (2014)
10.2478/fco-2014-0005
Impact of relatively new chemotherapeutic agents on the outcome of Egyptian patients with advanced malignant pleural mesothelioma
Rabab Gaafar (2014)
10.1016/J.RMR.2014.12.009
Échoendoscopie bronchique pour le diagnostic de mésothéliome pleural malin
J. Guinde (2015)
10.17795/RRO-3835
Pain Management in Mesothelioma
Nicholas Macleod (2015)
10.4415/ANN_15_01_09
Pathologic diagnosis of malignant mesothelioma: chronological prospect and advent of recommendations and guidelines.
V. Ascoli (2015)
10.1245/s10434-011-1728-x
Summary of Prognostic Factors and Patient Selection for Extrapleural Pneumonectomy in the Treatment of Malignant Pleural Mesothelioma
Mbbs Christopher Cao BSc (2011)
10.4172/2165-7386.1000223
Pain Management in Mesothelioma
Nicholas Macleod (2015)
10.4103/1687-8426.193645
Correlation between pleural fluid cytology and magnitude of pleural invasion in patients with malignant pleural mesothelioma
AmrM Shoukri (2016)
10.3389/fonc.2019.01519
Malignant Pleural Mesothelioma: State-of-the-Art on Current Therapies and Promises for the Future
Fabio Nicolini (2019)
10.1097/LBR.0000000000000294
Endobronchial Diagnosis of a Malignant Mesothelioma
Hooi Shan Yap (2016)
10.1183/2312508x.10032419
Radiology in pleural disease: what is the role of chest radiographs, CT and PET in modern management?
Laura Duerden (2020)
10.3892/MCO.2016.976
Membranous nephropathy associated with malignant pleural mesothelioma in an adult patient: A case report.
Xinyu Pu (2016)
See more
Semantic Scholar Logo Some data provided by SemanticScholar